CPIC A/B (N= 17 genes) | |||||
Finances of clinical testing | |||||
Used in RESEARCH | Used CLINICALLY | Billing patients | Billing 3rd party | Other sources of funding | |
Total | 11 | 15 | 2 | 11 | 8 |
% of PGx Testing sites | 73% | 100% | 13% | 73% | 53% |
CPIC C/D (N= 8 genes) | |||||
Finances of clinical testing | |||||
Used in RESEARCH | Used CLINICALLY | Billing patients | Billing 3rd party | Other sources of funding | |
Total | 7 | 2 | 1 | 1 | 3 |
% of PGx Testing sites | 47% | 13% | 7% | 7% | 20% |
No CPIC Rating (N= 15 genes) | |||||
Finances | |||||
Used in RESEARCH | Used CLINICALLY | Billing patients | Billing 3rd party | Other sources of funding | |
Total | 7 | 4 | 1 | 1 | 5 |
% of PGx Testing sites | 47% | 27% | 7% | 7% | 33% |